Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

2019/11/25 by Brian Skaug, Dinesh Khanna, William R Swindell +44 · 25 citations
Medicine · #Systemic Sclerosis and Related Diseases #Multiple Sclerosis Research Studies #Skin Diseases and Diabetes

paper · doi:10.1136/annrheumdis-2019-215894

Citations

• 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

Cited by

• Comparative profiling and comprehensive quantification of stratum corneum ceramides in humans and mice by LC/MS/MS. [europepmc]
• Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts. [europepmc]
• Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis. [europepmc]
• Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. [europepmc]
• New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. [europepmc]
• Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. [europepmc]
• Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. [europepmc]
• Current Concepts on the Pathogenesis of Systemic Sclerosis. [europepmc]
• Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. [europepmc]
• Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. [europepmc]
• Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. [europepmc]
• Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. [europepmc]
• Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. [europepmc]
• Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. [europepmc]
• Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation. [europepmc]
• Role of B-Cell in the Pathogenesis of Systemic Sclerosis. [europepmc]
• Dysregulated B cell function and disease pathogenesis in systemic sclerosis. [europepmc]
• Bacterial Metabolites: A Link between Gut Microbiota and Dermatological Diseases. [europepmc]
• Macrophage: Key player in the pathogenesis of autoimmune diseases. [europepmc]
• Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. [europepmc]
• Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups. [europepmc]
• Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features. [europepmc]
• Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis. [europepmc]
• Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis. [europepmc]
• Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. [europepmc]